Celestica Inc vs Summit Therapeutics Inc — how do they compare? Celestica Inc trades at $338.76 (market cap $39.16B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Celestica Inc is far larger — about 3.2× Summit Therapeutics Inc's market cap, and Celestica Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| CLS | SMMT | |
|---|---|---|
Market Cap | $39.16B | $12.06B |
Sector | Technology | Health |
52-Week High | $472.40 | $26.98 |
52-Week Low | $181.34 | $12.55 |
Enterprise Value | $39.44B | $11.39B |
Signals from Pluang's Aura AI — not financial advice
CLS trades at $339.46, up 7.91% in 24 hours, with a bearish technical signal but strong fundamentals. Recent Q2 2026 EPS of $2.54 beat estimates, and revenue growth is driven by AI infrastructure demand. The company completed a $3 billion equity offering to fund expansion, though this may cause near-term dilution. Support levels are near $309, with resistance at $313.
Outlook is positive due to robust earnings beats and AI-driven growth, but risks include equity dilution and premium valuation. Analyst consensus is bullish with a $466.50 price target, indicating 37% upside. Investors should weigh growth potential against execution risks and market volatility.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Trailing returns across standard periods
Latest headlines on both assets
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →